The Graft Injury Group is funded by the European Society of Gastroenterology, Hepatology & Nutrition (ESPGHAN) and European Association for the Study of Liver (EASL) and is independent of the pharmaceutical and medical devices industries.
However, the work of these industries is vital for the development of new treatments for supporting graft survival and patient quality of life, so a key goal of GIG is to collaborate with industry to improve treatment for people post transplantation. Industry researchers wishing to discuss collaboration opportunities are welcome to make contact by email: